Coronavirus: DiaSorin patents test for diagnosis in 60 minutes

The multinational pharmaceutical company DiaSorin is ready to launch a new test that will prove positive for Coronavirus in just 60 minutes.

In the fight against Coronavirus, every minute can be decisive to save lives. A fast (and reliable) diagnosis in cases of suspected contagion is indeed essential to guide the work of doctors and healthcare professionals. Precisely for this reason, research centers and laboratories around the world are working to develop tests and systems to identify the Coronavirus. Just a few hours ago, a team funded by e-commerce giant Alibaba announced the creation of software that uses Artificial Intelligence to provide a reliable diagnosis in few seconds. Today, the pharmaceutical giant DiaSorin has also announced that it has developed a molecular test capable of delivering very accurate results in less than 60 minutes. This will save a lot of time: with the swab currently in use in Italian hospitals, waiting times range from 5 to 7 hours. DiaSorin’s molecular test has already obtained the regulatory and regulatory green light and is awaiting the latest authorization from the Food and Drug Administration, the U.S. government agency that regulates the distribution of drugs and medical devices. In a note, the Company’s top management has indicated that the final okay should arrive by March 30. From this date, the company intends to distribute 100/150 thousand tests to Italian hospitals.

DiaSorin test: how to make a quick diagnosis

In an official note, DiaSorin explained that the test was developed to be run on the Liaison Mdx analyzer. Thanks to its direct amplification disk it will allow reliable results to be obtained in less than 60 minutes. “We started as soon as the information on the genetic sequence of the virus was made public, working with Italian and U.S. reference centers to develop fast and accurate molecular tests to address this health emergency,” said Giulia Minnucci, Research & Development Director Europe DiaSorin. “We have analyzed over 150 virus sequences published today in the worldwide gene bank database and designed a test to detect all currently known variants of the Coronavirus COVID-19″. John Gerace, president of the DiaSorin Molecular Department, also stressed the company’s commitment to the fight against the Coronavirus. “We believe it is of paramount importance to develop a Coronavirus identification test that can provide accurate results quickly and guide clinical decisions. As diagnostics specialists, we have a duty to respond to this emergency as quickly as possible by mobilizing our researchers to develop a molecular diagnostic test that we hope will help contain this new health emergency”.

You may also be interested in —> Coronavirus: schools closed? Lessons in Augmented Reality are starting

Exit mobile version